News | June 08, 2026
Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Community healthcare initiatives reach a milestone year, with services spanning 90 districts, 22 states, and over 70 lakh cumulative beneficiaries since 2006
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Targeting deadly drug-resistant acinetobacter infections
The move signals a major expansion in access to next-generation weight-loss therapies
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
Subscribe To Our Newsletter & Stay Updated
